BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

2.

Gandhi

UH

,

Cornell

RF

,

Lakshman

A

, et al.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

.

Leukemia

.

2019

;

33

(

9

):

2266

-

2275

.

3.

Karwacz

K

,

Hooper

AT

,

Chang

C-PB

, et al.

Abstract 4557: BCMA-CD3 bispecific antibody PF-06863135: preclinical rationale for therapeutic combinations

.

Cancer Res

.

2020

;

80

(

suppl 16

). 4557-4557.

4.

Pillarisetti

K

,

Powers

G

,

Luistro

L

, et al.

Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

.

Blood Adv

.

2020

;

4

(

18

):

4538

-

4549

.

5.

Moreau

P

,

Garfall

AL

,

van de Donk

N

, et al.

Teclistamab in relapsed or refractory multiple myeloma

.

N Engl J Med

.

2022

;

387

(

6

):

495

-

505

.

6.

van de Donk

NW

,

Moreau

P

,

Garfall

AL

, et al.

Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)

.

J Clin Oncol

.

2023

;

41

(

suppl 16

). 8011-8011.

7.

Bahlis

NJ

,

Costello

CL

,

Raje

NS

, et al.

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

.

Nat Med

.

2023

;

29

(

10

):

2570

-

2576

.

8.

Lesokhin

AM

,

Tomasson

MH

,

Arnulf

B

, et al.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

.

Nat Med

.

2023

;

29

(

9

):

2259

-

2267

.

9.

Usmani

SZ

,

Karlin

L

,

Benboubker

L

, et al.

Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study

.

J Clin Oncol

.

2023

;

41

(

suppl 16

):

8034

.

10.

Lee

HC

,

Bumma

N

,

Richter

JR

, et al.

LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma

.

J Clin Oncol

.

2023

;

41

(

suppl 16

). 8006-8006.

11.

Wong

SW

,

Bar

N

,

Paris

L

, et al.

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

400

-

402

.

12.

Bar

N

,

Mateos

MV

,

Ribas

P

, et al.

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) × CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

2011

.

13.

D'Souza

A

,

Shah

N

,

Rodriguez

C

, et al.

A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma

.

J Clin Oncol

.

2022

;

40

(

31

):

3576

-

3586

.

14.

Madan

S

,

Costello

CL

,

Lipe

B

, et al.

Results from the completed dose escalation portion of the phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC®) targeting B cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma (MM) [abstract]

.

Blood

.

2023

;

142

(

suppl 1

). 1012-1012.

15.

Vij

R

,

Kumar

SK

,

D’Souza

A

, et al.

Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

3378

.

16.

Chari

A

,

Minnema

MC

,

Berdeja

JG

, et al.

Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma

.

N Engl J Med

.

2022

;

387

(

24

):

2232

-

2244

.

17.

Schinke

CD

,

Touzeau

C

,

Minnema

MC

, et al.

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM)

.

J Clin Oncol

.

2023

;

41

(

suppl 16

):

8036

.

18.

Carlo-Stella

C

,

Mazza

R

,

Manier

S

, et al.

RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

397

-

399

.

19.

Harrison

JS

,

Riley

CH

,

Manier

S

, et al.

Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: analysis of patient- and disease-related factors associated with responses

.

Clin Lymphoma Myeloma Leuk

.

2023

;

23

:

S3

-

S4

.

20.

Mailankody

S

,

Devlin

SM

,

Landa

J

, et al.

GPRC5D-targeted CAR T cells for myeloma

.

N Engl J Med

.

2022

;

387

(

13

):

1196

-

1206

.

21.

Jakubowiak

AJ

,

Anguille

S

,

Karlin

L

, et al.

Updated results of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma with prior exposure to t-cell redirecting therapies: results of the phase 1/2 MonumenTAL-1 study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

3377

.

22.

Smith

EL

,

Harrington

K

,

Staehr

M

, et al.

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

.

Sci Transl Med

.

2019

;

11

(

485

):

eaau7746

.

23.

Sanchez

E

,

Li

M

,

Kitto

A

, et al.

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

.

Br J Haematol

.

2012

;

158

(

6

):

727

-

738

.

24.

Cortes-Selva

D

,

Casneuf

T

,

Vishwamitra

D

, et al.

Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): correlative analyses from MajesTEC-1 [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

241

-

243

.

25.

Miao

X

,

Wu

LS

,

Lin

SXW

, et al.

Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed/refractory multiple myeloma: results from MajesTEC-1

.

Target Oncol

.

2023

;

18

(

5

):

667

-

684

.

26.

Girgis

S

,

Wang Lin

SX

,

Pillarisetti

K

, et al.

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

.

Blood Adv

.

2023

;

7

(

4

):

644

-

648

.

27.

Elmeliegy

M

,

Kei

Lon H

,

Wang

D

, et al.

Soluble B-cell maturation antigen as a disease biomarker in relapsed or refractory multiple myeloma (RRMM): evaluation from elranatamab (ELRA) magnetismm studies [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

3345

.

28.

Lee

H

,

Durante

M

,

Ahn

S

, et al.

The impact of soluble BCMA and BCMA gain on anti-BCMA immunotherapies in multiple myeloma [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

4688

.

29.

Chen

H

,

Li

M

,

Xu

N

, et al.

Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells

.

Leuk Res

.

2019

;

81

:

62

-

66

.

30.

Kei

Lon H

,

Hibma

J

,

Williams

J

, et al.

Elranatamab exposure-efficacy analysis in patients with relapsed or refractory multiple myeloma: insights from pooled magnetismm studies [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1995

.

31.

Chen

H

,

Yu

T

,

Lin

L

, et al.

γ-Secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation

.

Blood Cancer J

.

2022

;

12

(

8

):

118

.

32.

Offner

F

,

Decaux

O

,

Hulin

C

, et al.

S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY

.

Hemasphere

.

2023

;

7

(

suppl

):

e1257964

.

33.

Landgren

O

,

Kazandjian

D

,

O’Connell

A

,

Finn

G

,

Raje

N

.

Magnetismm-4: an open label, phase 1b/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

10172

-

10173

.

34.

Meermeier

EW

,

Welsh

SJ

,

Sharik

ME

, et al.

Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy

.

Blood Cancer Discov

.

2021

;

2

(

4

):

354

-

369

.

35.

Hansen

JD

,

Correa

M

,

Nagy

MA

, et al.

Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma

.

J Med Chem

.

2020

;

63

(

13

):

6648

-

6676

.

36.

Cho

SF

,

Lin

L

,

Xing

L

, et al.

The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models

.

Blood Adv

.

2020

;

4

(

17

):

4195

-

4207

.

37.

Frerichs

KA

,

Broekmans

MEC

,

Marin Soto

JA

, et al.

Preclinical activity of JNJ-7957, a novel BCMA×CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab

.

Clin Cancer Res

.

2020

;

26

(

9

):

2203

-

2215

.

38.

Matous

J

,

Biran

N

,

Perrot

A

, et al.

Talquetamab + pomalidomide in patients with relapsed/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1014

.

39.

Friedrich

MJ

,

Neri

P

,

Kehl

N

, et al.

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

.

Cancer Cell

.

2023

;

41

(

4

):

711

-

725.e6

.

40.

Lee

H

,

Ahn

S

,

Maity

R

, et al.

Immune and genome profiling of myeloma patients treated with sequential immunotherapies reveal differential non-overlapping mechanisms of resistance [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1945

.

41.

Rasche

L

,

Truger

M

,

Munawar

U

, et al.

OA-24 sequential and persistent loss of BCMA and GPRC5D after bispecific antibodies in multiple myeloma revealed by whole genome sequencing

.

Clin Lymphoma Myeloma Leukemia

.

2023

;

23

:

S15

.

42.

Duell

J

,

Dittrich

M

,

Bedke

T

, et al.

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

.

Leukemia

.

2017

;

31

(

10

):

2181

-

2190

.

43.

Vafa

O

,

Trinklein

ND

.

Perspective: designing T-cell engagers with better therapeutic windows

.

Front Oncol

.

2020

;

10

:

446

.

44.

Krejcik

J

,

Casneuf

T

,

Nijhof

IS

, et al.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

.

Blood

.

2016

;

128

(

3

):

384

-

394

.

https://doi.org/10.1182/bloodadvances.2023011225

45.

Firestone

RS

,

McAvoy

D

,

Shekarkhand

T

, et al.

CD8 effector T cells enhance response in BCMA-exposed and -naïve multiple myeloma

.

Blood Adv

.

Published online 25 October 2023

.

46.

van de Donk

NW

,

Bahlis

N

,

Mateos

M-V

, et al.

S183: novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1B results for talquetamab (a GPRC5D X CD3 bispecific antibody) in combination with daratumumab

.

HemaSphere

.

2022

;

6

:

84

-

85

.

47.

Lee

H

,

Neri

P

,

Bahlis

NJ

.

Current use of bispecific antibodies to treat multiple myeloma

.

Hematology

.

2023

;

2023

(

1

):

332

-

339

.

48.

Lee

H

,

Ahn

S

,

Maity

R

, et al.

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

.

Nat Med

.

2023

;

29

(

9

):

2295

-

2306

.

49.

Truger

MS

,

Duell

J

,

Zhou

X

, et al.

Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM

.

Blood Adv

.

2021

;

5

(

19

):

3794

-

3798

.

50.

Da Vià

MC

,

Dietrich

O

,

Truger

M

, et al.

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

.

Nat Med

.

2021

;

27

(

4

):

616

-

619

.

51.

Samur

MK

,

Fulciniti

M

,

Aktas Samur

A

, et al.

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

.

Nat Commun

.

2021

;

12

(

1

):

868

.

52.

Mi

X

,

Penson

A

,

Abdel-Wahab

O

,

Mailankody

S

.

Genetic basis of relapse after GPRC5D-targeted CAR T cells

.

N Engl J Med

.

2023

;

389

(

15

):

1435

-

1437

.

53.

Derrien

J

,

Gastineau

S

,

Frigout

A

, et al.

Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation

.

Nat Cancer

.

2023

;

4

(

11

):

1536

-

1543

.

54.

Samur

MK

,

Aktas Samur

A

,

Corre

J

, et al.

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma

.

Blood Adv

.

2023

;

7

(

21

):

6599

-

6603

.

55.

Santich

BH

,

Park

JA

,

Tran

H

,

Guo

HF

,

Huse

M

,

Cheung

NKV

.

Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies

.

Sci Transl Med

.

2020

;

12

(

534

):

eaax1315

.

56.

Bacac

M

,

Colombetti

S

,

Herter

S

, et al.

CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies

.

Clin Cancer Res

.

2018

;

24

(

19

):

4785

-

4797

.

57.

Cohen

YC

,

Morillo

D

,

Gatt

ME

, et al.

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

.

J Clin Oncol

.

2023

;

41

(

suppl 16

):

8002

.

58.

Trudel

S

,

Cohen

AD

,

Krishnan

AY

, et al.

Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

157

.

59.

Hansen

DK

,

Sidana

S

,

Peres

LC

, et al.

Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium

.

J Clin Oncol

.

2023

;

41

(

11

):

2087

-

2097

.

60.

Cohen

AD

,

Mateos

M-V

,

Cohen

YC

, et al.

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

.

Blood

.

2023

;

141

(

3

):

219

-

230

.

61.

Van Oekelen

O

,

Nath

K

,

Mouhieddine

TH

, et al.

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

.

Blood

.

2023

;

141

(

7

):

756

-

765

.

62.

Touzeau

C

,

Krishnan

AY

,

Moreau

P

, et al.

Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents

.

J Clin Oncol

.

2022

;

40

(

suppl 16

):

8013

.

63.

Dholaria

BR

,

Weisel

K

,

Mateos

M-V

, et al.

Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated TRIMM-2 results

.

J Clin Oncol

.

2023

;

41

(

suppl 16

):

8003

.

64.

Kumar

S

,

Bachier

CR

,

Cavo

M

, et al.

CAMMA 2: a phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent

.

J Clin Oncol

.

2023

;

41

(

suppl 16

):

TPS8064

.

65.

Philipp

N

,

Kazerani

M

,

Nicholls

A

, et al.

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

.

Blood

.

2022

;

140

(

10

):

1104

-

1118

.

66.

Lesokhin

AM

,

Richter

J

,

Trudel

S

, et al.

Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed/refractory multiple myeloma: early experience from a phase I study [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

4415

-

4417

.